Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

Breast Cancer Research and Treatment
Kathleen I PritchardPatrick Neven

Abstract

The Faslodex Investigation of Dose evaluation in Estrogen Receptor-positive advanced breast cancer (FINDER)2 study evaluated the efficacy, safety, and pharmacokinetics (PK) of three fulvestrant dosing regimens. FINDER2 enrolled Western postmenopausal women recurring or progressing after prior endocrine therapy. Primary endpoint: objective response rate (ORR); secondary endpoints: time to progression (TTP), clinical benefit rate (CBR), tolerability, and PK parameters. Patients were randomized to receive fulvestrant: 250 mg/month (approved dose [AD]); 250 mg plus loading dose (loading dose [LD]; 500 mg on day 0, 250 mg on days 14, 28, and monthly thereafter); or 500 mg (high dose [HD]; 500 mg/month plus 500 mg on day 14 of Month 1). Treatment continued until disease progression or discontinuation. 144 patients were randomized: fulvestrant AD (n = 47); LD (n = 51); HD (n = 46). ORRs were: 8.5% (95% confidence interval [CI]: 2.4, 20.4%), 5.9% (1.2, 16.2%), and 15.2% (6.3, 28.9%) in the AD, LD, and HD arms, respectively. CBRs were: 31.9% (95% CI: 19.1, 47.1%), 47.1% (32.9, 61.5%), and 47.8% (32.9, 63.1%) for the AD, LD, and HD arms, respectively. Median TTP (months) was numerically longer for HD (6.0) and LD (6.1) versus AD (3.1). T...Continue Reading

References

Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HowellC Morris
Jun 2, 2004·Clinical Pharmacokinetics·John F R RobertsonDavid A Clarke
Feb 14, 2006·Critical Reviews in Oncology/hematology·Anthony Howell
Aug 4, 2007·The Oncologist·John F R Robertson
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John F R RobertsonMatthew J Ellis
May 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S OhnoS Noguchi

❮ Previous
Next ❯

Citations

Jul 25, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Christina BjerreJan Stenvang
Jan 5, 2011·Breast Cancer Research : BCR·Anthony Howell
Feb 11, 2012·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Seiichi YanoLan Chen
Nov 5, 2011·Expert Review of Anticancer Therapy·Jonathan KrellCarlo Palmieri
Nov 30, 2011·Expert Opinion on Emerging Drugs·Cagatay ArslanOmer Dizdar
Feb 18, 2011·Expert Opinion on Pharmacotherapy·Simon SpazzapanAndrea Veronesi
Aug 7, 2013·Hematology/oncology Clinics of North America·Gaia Schiavon, Ian E Smith
Dec 12, 2012·Clinical Breast Cancer·Rowan T Chlebowski
Jul 17, 2012·Cancer Treatment Reviews·L EstévezA Lluch
Sep 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alexandre Bodmer, Monica Castiglione-Gertsch
Jul 7, 2011·Clinical Breast Cancer·Angela Mae Obermiller, Mehmet Sitki Copur
Jul 7, 2011·Clinical Breast Cancer·Anthony Howell, Francisco Sapunar
Apr 22, 2015·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Naoko IshidaHiroko Yamashita
Mar 30, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Shannon CopePeter Schmid
Mar 13, 2012·Molecular Oncology·Shannon PuhallaNancy E Davidson
Dec 3, 2014·Clinical Breast Cancer·John F R RobertsonJulia M W Gee
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony Howell, Jonas Bergh
May 25, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hope S RugoHarold J Burstein
Feb 24, 2012·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Matthew J NewmanRoger A Edwards
May 23, 2018·Future Oncology·Maryam Nemati Shafaee, Matthew James Ellis
May 12, 2018·Expert Review of Anticancer Therapy·Sophie A BlackburnKwok-Leung Cheung
Feb 8, 2019·Expert Opinion on Pharmacotherapy·Palma FedeleSaverio Cinieri
Jul 7, 2017·Oncology and Therapy·Mark R Nathan, Peter Schmid
Sep 17, 2013·The Oncologist·Vishal SaggarMario E Lacouture
Sep 6, 2019·Expert Opinion on Pharmacotherapy·Mohsin SolejaNisha Unni
Jan 27, 2019·British Journal of Cancer·Laura J OwenSacha Howell
May 13, 2019·Breast Cancer : the Journal of the Japanese Breast Cancer Society·John F R RobertsonChristine Campbell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

© 2021 Meta ULC. All rights reserved